Evidence map›Paper›PMID 27154636›Full record

ArticleMedical oncology (Northwood, London, England)2016

Rap2B promotes cell proliferation, migration and invasion in prostate cancer.

Jiehui Di, Huan Cao, Juangjuan Tang, Zheng Lu, Keyu Gao, Zhesi Zhu, Junnian Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. miRNA-17 promotes nasopharyngeal carcinoma radioresistance by targeting PTEN/AKT.International journal of clinical and experimental pathology · 2019
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jiehui DiCancer Institute, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China.
Huan CaoCancer Institute, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China.
Juangjuan TangCancer Institute, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China.
Zheng LuCancer Institute, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China.
Keyu GaoCancer Institute, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China.
Zhesi ZhuCancer Institute, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China.
Junnian ZhengCancer Institute, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China. jnzheng@xzmc.edu.cn.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rap2B, a member of the Ras family of small GTP-binding proteins, reportedly presents a high level of expression in various human tumors and plays a significant role in the development of tumor. However, the function of Rap2B in prostate cancer (PCa) remains unclear. We elucidated the stimulative role of Rap2B in PCa cell proliferation, migration and invasion by means of the CCK-8 cell proliferation assay, cell cycle analysis and transwell migration assay. Western blot analysis uncovered that elevated Rap2B leads to increased phosphorylation levels of FAK, suggesting that FAK-dependent pathway might be responsible for the effect of Rap2B on PCa cells migration and invasion. Inversely, FAK-specific inhibitor (PF-573228) can abort Rap2B-induced FAK phosphorylation. In vivo experiment confirmed that Rap2B positively regulated PCa growth and metastasis, as well as the expression of phosphorylated FAK. Collectively, these findings shed light on Rap2B as a potential therapeutic target for PCa.

Indexed as

AnimalsCell Line, TumorCell MovementCell ProliferationFocal Adhesion Kinase 1HeterograftsHumansMaleMiceMice, Inbred BALB CMice, NudeNeoplasm InvasivenessNeoplasm MetastasisPhosphorylationProstatic Neoplasmsrap GTP-Binding ProteinsFocal Adhesion Kinase 1PTK2 protein, humanRAP2B protein, humanrap GTP-Binding ProteinsFAKMigrationProstate cancerRap2B

Identifiers

PMID27154636
OpenAlexW2346709631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.